13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002018299
Total reported value
$1.3B
$1.3B
34 檔
13.4%
During the Q3 2025 filing period, Boxer Capital Management, LLC (CIK: 0002018299) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.3B across 34 reported positions.
In Q3 2025, Boxer Capital Management, LLC displayed an active expansion posture, initiating 15 new positions and adding to 2 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics Inc | Stock-Other | 26.16% | -4.26% | — | |
| 2 | QURE | uniQure N.V. | Stock-Other | 14.88% | +3.79% | -11.06% | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 5.95% | +0.67% | -49.56% | |
| 4 | KYMR | Kymera Therapeutics Inc | Stock-Other | 5.76% | +0.11% | -26.14% | |
| 5 | KOD | Kodiak Sciences Inc | Stock-Other | 3.91% | -2.47% | — | |
| 6 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 3.91% | -0.56% | — | |
| 7 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 3.90% | -0.38% | -26.53% | |
| 8 | URGN | UroGen Pharma Ltd. | Stock-Other | 3.66% | +0.21% | — | |
| 9 | ✓ | Merus N V | Stock-Other | 3.60% | — | -67.12% | |
| 10 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.50% | -0.23% | — | |
| 11 | ABVX | Abivax Sa-adr | Stock-Other | 3.25% | +3.15% | — | |
| 12 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.33% | -0.78% | +83.33% | |
| 13 | NKTR | Nektar Therapeutics | Stock-Other | 2.27% | — | — | |
| 14 | ✓ | Crescent Biopharma Inc. | Stock-Other | 1.72% | — | — | |
| 15 | INO | Inovio Pharmaceuticals Inc | Stock-Other | 1.72% | -0.30% | — | |
| 16 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.54% | -0.23% | +900.00% | |
| 17 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.47% | — | -12.73% | |
| 18 | CELC | Celcuity Inc | Stock-Other | 1.42% | -0.09% | — | |
| 19 | REPL | Replimune Group Inc | Stock-Other | 1.40% | +2.14% | -52.52% | |
| 20 | SLDB | Solid Biosciences Inc | Stock-Other | 1.18% | -0.05% | — | |
| 21 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.16% | — | — | |
| 22 | PGEN | Precigen Inc | Stock-Other | 0.89% | +0.43% | — | |
| 23 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.63% | -0.07% | — | |
| 24 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.61% | — | — | |
| 25 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.57% | -0.27% | — | |
| 26 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.52% | -0.02% | — | |
| 27 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.51% | -0.07% | — | |
| 28 | MIST | Milestone Pharmaceuticals In | Stock-Other | 0.42% | -0.03% | — | |
| 29 | PEPG | Pepgen Inc | Stock-Other | 0.37% | -0.02% | — | |
| 30 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 0.35% | -0.06% | — | |
| 31 | TIL | Instil Bio Inc | Stock-Other | 0.35% | — | -14.14% | |
| 32 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.08% | -0.05% | EXIT | |
| 33 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.02% | — | — | |
| 34 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | QURE | uniQure N.V. | +8.6% | -11.06% | Trim |
| 2 | KOD | Kodiak Sciences Inc | +2.5% | — | Unchanged |
| 3 | SRPT | Sarepta Therapeutics Inc | +1.3% | +900.00% | Add |
| 4 | TNGX | Tango Therapeutics Inc | +1% | — | Unchanged |
| 5 | PTGX | Protagonist Therapeutics Inc | +0.7% | +83.33% | Add |
| 6 | NKTR | Nektar Therapeutics | +0.6% | — | Unchanged |
| 7 | CDTX | Cidara Therapeutics Inc | +0.1% | -12.73% | Trim |
| 8 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 9 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 10 | AMLX | Amylyx Pharmaceuticals Inc | -0.1% | -26.53% | Trim |
| 11 | URGN | UroGen Pharma Ltd. | -0.3% | — | Unchanged |
| 12 | TIL | Instil Bio Inc | -0.4% | -14.14% | Trim |
| 13 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.5% | -78.16% | Trim |
| 14 | NRIX | Nurix Therapeutics Inc | -0.5% | — | Unchanged |
| 15 | ✓ | Crescent Biopharma Inc. | -2% | — | Unchanged |
| 16 | KYMR | Kymera Therapeutics Inc | -3.7% | -26.14% | Trim |
| 17 | ✓ | Merus N V | -6.1% | -67.12% | Trim |
| 18 | RVMD | Revolution Medicines Inc | -8.7% | -49.56% | Trim |
| 19 | REPL | Replimune Group Inc | -8.9% | -52.52% | Trim |
| 20 | PTCT | Ptc Therapeutics Inc | — | NEW | New buy |
| 21 | CYTK | Cytokinetics Inc | — | NEW | New buy |
| 22 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 23 | 2662247D | Iteos Therapeutics Inc | — | EXIT | Sold out |
| 24 | INO | Inovio Pharmaceuticals Inc | — | NEW | New buy |
| 25 | CELC | Celcuity Inc | — | NEW | New buy |
| 26 | SLDB | Solid Biosciences Inc | — | NEW | New buy |
| 27 | DNLI | Denali Therapeutics Inc | — | NEW | New buy |
| 28 | PGEN | Precigen Inc | — | NEW | New buy |
| 29 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 30 | BRD1EUR | Mind Medicine Mindmed Inc | — | NEW | New buy |
| 31 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 32 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
| 33 | MIST | Milestone Pharmaceuticals In | — | NEW | New buy |
| 34 | PEPG | Pepgen Inc | — | NEW | New buy |
| 35 | LBRX | Lb Pharmaceuticals Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Boxer Capital Management, LLC reported a total U.S. public equity portfolio value of $1.3B across 34 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TNGX, QURE, RVMD) accounted for 13.4% of total reported equity market value during Q3 2025.
Top New Position Initiated
PTCT
市值: $12.3M
Top Position Liquidated / Trimmed
2662247D
前期市值: $8.2M
During Q3 2025, Boxer Capital Management, LLC's top holdings by market value included TNGX (26.2%)、QURE (14.9%)、RVMD (6.0%). The largest single position, TNGX, represented 26.2% of total portfolio value.
In Q3 2025, Boxer Capital Management, LLC made 27 total portfolio adjustments, initiating 15 new buys, adding to 2 positions, trimming 9 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.